Leaderboard

En | De
No articles selected!     View Cart  
You are here: Urology-Nephrology » Neoplasia/BPH 18. June 2026
Search
medline.ch
Neoplasia/BPH
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Inflammation-Infection
Nephrolithiasis
Renal Failure
Sexuality
Neoplasia/BPH
Others
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 9436  Previews Next
   
   Articles 1 - 20 / 188707  
   
Prostate Cancer - 20-Year Comparative Mortality and Survival Analysis by Age, Race/Ethnicity, Stage, Grade, Disease Duration and Cohort Entry Period: A Systematic Review of 648,114 cases for Diagnosis Years 1975-2022.
J Insur Med
Milano AF.
PMID: 42307551 [PubMed - indexed for MEDLINE]


Elevated serum Raftlin levels in non-muscle invasive bladder cancer: diagnostic implications and rs690037 genotype analysis.
Rev Assoc Med Bras (1992)
Balci S, Tanriverdi R, Nebio, Yildirim DD, Gülüm C, Bozlu M, Tamer L.
PMID: 42307354 [PubMed - indexed for MEDLINE]


Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions.
Cureus
Park J, Arshad H, Khan S, Vinod NP, Goel R, Vats D, Arshad I.
PMID: 42306392 [PubMed]


Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].
Eur Urol Open Sci
Bickley L, Fransen van de Putte EE, van den Brink L, Marandino L, van der Mijn JC, Wilgenhof S, van Thienen JV, Haanen JBAG, Boleti E, Powles T, Zondervan PJ, Graafland NM, Tippu Z, Turajlic S, Bex A.
PMID: 42305796 [PubMed]


Combining the PI-RADS v2.1 score with PSAD improves the diagnostic accuracy of transition zone prostate cancer.
Arch Med Sci
Zhong J, Ding J, Zhang Y, Yang Q.
PMID: 42305309 [PubMed]


First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
Ann Med
He J, Wang Y, Tang W, Gao X, Cai Y, Tang Y, Hu S.
PMID: 42304982 [PubMed - indexed for MEDLINE]


Editorial Comment on to Investigate Disparities in Strategies for Low-Risk Prostate Cancer by Facility Type Using the Japan Study Group of Prostate Cancer Database.
Int J Urol
Tohi Y, Merseburger AS, Sugimoto M.
PMID: 42304637 [PubMed - in process]


Kidney cancer burden in China from 1990 to 2023: A retrospective population-based observational study.
J Int Med Res
Bai Z, Wang S, Wang H, Wang Y, Huang G, Hou Y.
PMID: 42304621 [PubMed - indexed for MEDLINE]


Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.
Cancer Rep (Hoboken)
Sakurai H, Shiga M, Kandori S, Takahashi S, Omiya A, Ishida T, Matsuda K, Isoda B, Mathis BJ, Komine M, Iinuma M, Joraku A, Negoro H, Tsutsumi M, Inoue T, Miyazaki J, Nishiyama H.
PMID: 42304594 [PubMed - indexed for MEDLINE]


Incidence and Risk Factors of Postoperative Acute Kidney Injury in Colorectal Cancer Patients With Metabolic Syndrome: A Retrospective Cohort Study.
Ann Ital Chir
Zha Q, Xiong K, Wei M, Chen Y.
PMID: 42304146 [PubMed - indexed for MEDLINE]


Navigating work after prostate cancer treatment: a systematic review of qualitative research.
J Cancer Surviv
Tomic D, Keegel T, Schellack SK, Abdel-Malek L, Jander C, Hettige ST, MacFarlane E, Millar J, Walker-Bone K.
PMID: 42303926 [PubMed - as supplied by publisher]


A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.
Nat Commun
Larcher A, Traverso A, Scuri P, Capitanio U, Musso G, Canibus D, Barbieri S, Caivano L, Zambello A, Denti M, Campi R, Serni S, Granata S, Palmisano A, Vignale D, Montorsi F, Esposito A, Tacchetti C, Salonia A.
PMID: 42303642 [PubMed - as supplied by publisher]


Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo.
Clin Genitourin Cancer
McNeel DG, Eickhoff JC, Perez A, Liu G.
PMID: 42303538 [PubMed - as supplied by publisher]


Re: Final Overall Survival Results from EORTC 1333/PEACE-3 Trial of Enzalutamide plus Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Eur Urol
Francini E.
PMID: 42303526 [PubMed - as supplied by publisher]


Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.
Eur Urol
Mertens LS, Mellema JJ, Sridhar S, van der Heijden MS.
PMID: 42303524 [PubMed - as supplied by publisher]


Re: Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.
Eur Urol
Ma H, Zhou Q.
PMID: 42303523 [PubMed - as supplied by publisher]


Re: Stereotactic Body Radiation Therapy for Oligoprogressive Disease in Androgen-suppressed Prostate Cancer: Primary Endpoint Analysis of the TRAP Trial.
Eur Urol
Yusuf S, Azam A, Sood I, Al-Sattar H, Mullassery V, Adeleke S.
PMID: 42303522 [PubMed - as supplied by publisher]


Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.
Eur Urol Oncol
Light A, Peters M, Gopalakrishnan A, Mayor N, Freeman A, Emberton M, Ahmed HU, Shah TT.
PMID: 42303478 [PubMed - as supplied by publisher]


Prevalence of homologous recombination repair genes alterations in metastatic castration-resistant prostate cancer, a multicentric study.
Fr J Urol
Allaume P, Raby M, Nourieh M, Lespagnol A, Tallet A, Péricart S, Tantot J, Lindner V, Decaussin M, Callens C, Descotes F, Allory Y, Rioux-Leclercq N, Kammerer-Jacquet SF, Fromont G.
PMID: 42303208 [PubMed - as supplied by publisher]


Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer.
J Natl Compr Canc Netw
Scilipoti P, de Angelis M, Thibault C, , Del Giudice F, Contieri R, Hurle R, Subiela JD, Simone G, Proietti F, Mori K, Shariat S, D'Andrea D, Zamboni S, Suardi N, Tanaka H, Matsumoto S, Fujii Y, Bertolo R, Antonelli A, Diamant E, Vordos D, Gabriel PE, Harber T, Colombel M, Hanquiez P, Chatain V, Duquesne I, Borz MB, Verhoest G, Mauger De Varennes A, Surlemont L, Ghenassia M, Masson-Lecomte A, Peyrottes A, Lebacle C, Beniac P, Léon P, Larré S, Taha F, Marcq G, Szostek A, Pradere B, Calleris G, Audenet F, Xylinas E, Allory Y, Bajeot AS, Prost D, Grobet-Jeandin E, Montorsi F, Necchi A, Briganti A, Moschini M, Roumiguié M, Rouprêt M, Seisen T.
PMID: 42302838 [PubMed - as supplied by publisher]


   
   Articles 1 - 20 / 188707    Page 1 of 9436  Previews Next

 
Rect Bottom
Adserver Footer
 

  Time frame  
   

Sky right 1